Literature DB >> 23117265

The emergence and dissemination of CTX-M-producing Escherichia coli sequence type 131 causing community-onset bacteremia in Israel.

D Karfunkel1, Y Carmeli, I Chmelnitsky, T Kotlovsky, S Navon-Venezia.   

Abstract

Community-onset bloodstream infections caused by extended-spectrum β-lactamase-producing Escherichia coli (ESBL-EC-COBSIs) were investigated over a 7-year-period (2003-2009) in our institution. ESBL-EC-COBSI inclusion criteria were cefotaxime/ceftazidime non-susceptible blood isolates recovered during 48 h upon hospital admission. Forty-one isolates were molecularly characterized. Susceptibilities were determined (Vitek-2) and genotyping was performed [multilocus sequence typing (MLST)]. CTX-M genes were determined [polymerase chain reaction (PCR) and sequencing] and bla CTX-M-encoding plasmids (n = 10) were analyzed and compared. Phylogrouping and virulence genes were identified (PCR). The incidence rate of ESBL-EC-COBSIs has increased from 2.94 to 7.87 cases/10,000 admissions. All isolates were multidrug-resistant (MDR), displaying co-resistance to ciprofloxacin (93 %), trimethoprim-sulfamethoxazole (85 %), and gentamicin (51 %). MLST identified ten sequence types (STs), of which five were novel. ST131 accounted for 66 % of the cases (27/41), and dominated over the years (prevalence of 25 % in 2003 and 85 % in 2009). All isolates carried CTX-M genes with the following prevalence: bla CTX-M-2 (6/8; 75 %) in 2003; bla CTX-M-15 (9/13, 69 % in 2007); and bla CTX-M-15 (11/20, 55 %) and bla CTX-M-14 (7/20, 35 %) in 2009. bla CTX-M-15- and bla CTX-M-14-encoding plasmids harbored by ST131 differed. Of all isolates, 98 % belonged to virulent phylogroups B2 (28/41, 68 %) and D (12/41, 29 %), though ST131 isolates carried a higher number of virulence genes compared to other lineages (p < 0.05). The incidence of ESBL-EC-COBSIs increased 2.7-fold during the period 2003-2009. This increase appears to be related to the emergence and clonal expansion of bla CTX-M-15- or bla CTX-M-14-carrying ST131. The superiority of this virulent lineage should be further explored.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23117265     DOI: 10.1007/s10096-012-1765-9

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  31 in total

1.  Rapid and simple determination of the Escherichia coli phylogenetic group.

Authors:  O Clermont; S Bonacorsi; E Bingen
Journal:  Appl Environ Microbiol       Date:  2000-10       Impact factor: 4.792

Review 2.  The CTX-M beta-lactamase pandemic.

Authors:  Rafael Cantón; Teresa M Coque
Journal:  Curr Opin Microbiol       Date:  2006-08-30       Impact factor: 7.934

3.  First national surveillance of susceptibility of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella spp. to antimicrobials in Israel.

Authors:  Raul Colodner; Zmira Samra; Nathan Keller; Hanna Sprecher; Colin Block; Nehama Peled; Tzilia Lazarovitch; Rita Bardenstein; Orna Schwartz-Harari; Yehuda Carmeli
Journal:  Diagn Microbiol Infect Dis       Date:  2007-02       Impact factor: 2.803

4.  CTX-M-2 and a new CTX-M-39 enzyme are the major extended-spectrum beta-lactamases in multiple Escherichia coli clones isolated in Tel Aviv, Israel.

Authors:  Inna Chmelnitsky; Yehuda Carmeli; Azita Leavitt; Mitchell J Schwaber; Shiri Navon-Venezia
Journal:  Antimicrob Agents Chemother       Date:  2005-11       Impact factor: 5.191

5.  Phylogenetic analysis and prevalence of urosepsis strains of Escherichia coli bearing pathogenicity island-like domains.

Authors:  Martine Bingen-Bidois; Olivier Clermont; Stéphane Bonacorsi; Mustapha Terki; Naïma Brahimi; Chawki Loukil; Dominique Barraud; Edouard Bingen
Journal:  Infect Immun       Date:  2002-06       Impact factor: 3.441

Review 6.  Extended-spectrum beta-lactamases: a clinical update.

Authors:  David L Paterson; Robert A Bonomo
Journal:  Clin Microbiol Rev       Date:  2005-10       Impact factor: 26.132

7.  Bacteremia due to extended-spectrum beta -lactamase-producing Escherichia coli in the CTX-M era: a new clinical challenge.

Authors:  Jesús Rodríguez-Baño; Maria D Navarro; Luisa Romero; Miguel A Muniain; Marina de Cueto; María J Ríos; José R Hernández; Alvaro Pascual
Journal:  Clin Infect Dis       Date:  2006-10-25       Impact factor: 9.079

8.  The CTX-M-15-producing Escherichia coli diffusing clone belongs to a highly virulent B2 phylogenetic subgroup.

Authors:  Olivier Clermont; Marie Lavollay; Sophie Vimont; Catherine Deschamps; Christiane Forestier; Catherine Branger; Erick Denamur; Guillaume Arlet
Journal:  J Antimicrob Chemother       Date:  2008-03-11       Impact factor: 5.790

9.  Host and bacterial determinants of initial severity and outcome of Escherichia coli sepsis.

Authors:  F Jauréguy; E Carbonnelle; S Bonacorsi; C Clec'h; P Casassus; E Bingen; B Picard; X Nassif; O Lortholary
Journal:  Clin Microbiol Infect       Date:  2007-07-06       Impact factor: 8.067

Review 10.  Aerobactin production as a virulence factor: a reevaluation.

Authors:  V de Lorenzo; J L Martinez
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1988-10       Impact factor: 3.267

View more
  17 in total

Review 1.  Escherichia coli ST131, an intriguing clonal group.

Authors:  Marie-Hélène Nicolas-Chanoine; Xavier Bertrand; Jean-Yves Madec
Journal:  Clin Microbiol Rev       Date:  2014-07       Impact factor: 26.132

2.  Global Extraintestinal Pathogenic Escherichia coli (ExPEC) Lineages.

Authors:  Amee R Manges; Hyun Min Geum; Alice Guo; Thaddeus J Edens; Chad D Fibke; Johann D D Pitout
Journal:  Clin Microbiol Rev       Date:  2019-06-12       Impact factor: 26.132

3.  Whole-genome comparison of urinary pathogenic Escherichia coli and faecal isolates of UTI patients and healthy controls.

Authors:  Karen Leth Nielsen; Marc Stegger; Kristoffer Kiil; Paul A Godfrey; Michael Feldgarden; Berit Lilje; Paal S Andersen; Niels Frimodt-Møller
Journal:  Int J Med Microbiol       Date:  2017-09-14       Impact factor: 3.473

4.  Epidemic Emergence in the United States of Escherichia coli Sequence Type 131-H30 (ST131-H30), 2000 to 2009.

Authors:  James R Johnson; Stephen Porter; Paul Thuras; Mariana Castanheira
Journal:  Antimicrob Agents Chemother       Date:  2017-07-25       Impact factor: 5.191

Review 5.  Extended-Spectrum β-Lactamase-Producing Enterobacteriaceae: Update on Molecular Epidemiology and Treatment Options.

Authors:  Gisele Peirano; Johann D D Pitout
Journal:  Drugs       Date:  2019-09       Impact factor: 9.546

Review 6.  Population-based epidemiology and microbiology of community-onset bloodstream infections.

Authors:  Kevin B Laupland; Deirdre L Church
Journal:  Clin Microbiol Rev       Date:  2014-10       Impact factor: 26.132

7.  First description of OXA-48-producing Escherichia coli and the pandemic clone ST131 from patients hospitalised at a military hospital in Algeria.

Authors:  A Agabou; A Pantel; Z Ouchenane; N Lezzar; S Khemissi; D Satta; A Sotto; J-P Lavigne
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2014-05-05       Impact factor: 3.267

8.  Clonal relationship between human and avian ciprofloxacin-resistant Escherichia coli isolates in North-Eastern Algeria.

Authors:  A Agabou; N Lezzar; Z Ouchenane; S Khemissi; D Satta; A Sotto; J-P Lavigne; A Pantel
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2015-12-03       Impact factor: 3.267

9.  Comparison of host response mechanisms evoked by extended spectrum beta lactamase (ESBL)--and non-ESBL-producing uropathogenic E. coli.

Authors:  Isak Demirel; Annica Kinnunen; Anna Onnberg; Bo Söderquist; Katarina Persson
Journal:  BMC Microbiol       Date:  2013-08-02       Impact factor: 3.605

10.  The antibacterial effect of nitric oxide against ESBL-producing uropathogenic E. coli is improved by combination with miconazole and polymyxin B nonapeptide.

Authors:  Charlotte Sahlberg Bang; Annica Kinnunen; Marie Karlsson; Anna Önnberg; Bo Söderquist; Katarina Persson
Journal:  BMC Microbiol       Date:  2014-03-14       Impact factor: 3.605

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.